journal article·2022-12-27Open access

Integration of In Vitro and In Vivo Models to Predict Cellular and Tissue Dosimetry of Nanomaterials Using Physiologically Based Pharmacokinetic Modeling

Zhoumeng Lin, Santosh Aryal, Yi-Hsien Cheng, Andre J. Gesquiere

ACS Nano· Volume 16· Issue 12

Abstract

Nanomaterials (NMs) have been increasingly used in a number of areas, including consumer products and nanomedicine. Target tissue dosimetry is important in the evaluation of safety, efficacy, and potential toxicity of NMs. Current evaluation of NM efficacy and safety involves the time-consuming collection of pharmacokinetic and toxicity data in animals and is usually completed one material at a time. This traditional approach no longer meets the demand of the explosive growth of NM-based products. There is an emerging need to develop methods that can help design safe and effective NMs in an efficient manner. In this review article, we critically evaluate existing studies on in vivo pharmacokinetic properties, in vitro cellular uptake and release and kinetic modeling, and whole-body physiologically based pharmacokinetic (PBPK) modeling studies of different NMs. Methods on how to simulate in vitro cellular uptake and release kinetics and how to extrapolate cellular and tissue dosimetry of NMs from in vitro to in vivo via PBPK modeling are discussed. We also share our perspectives on the current challenges and future directions of in vivo pharmacokinetic studies, in vitro cellular uptake and kinetic modeling, and whole-body PBPK modeling studies for NMs. Finally, we propose a nanomaterial in vitro to in vivo extrapolation via physiologically based pharmacokinetic modeling (Nano-IVIVE-PBPK) framework for high-throughput screening of target cellular and tissue dosimetry as well as potential toxicity of different NMs in order to meet the demand of efficient evaluation of the safety, efficacy, and potential toxicity of a rapidly increasing number of NM-based products.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida 32610, United States

Center for Environmental and Human Toxicology, University of Florida, Gainesville, Florida 32608, United States

Department of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, The University of Texas at Tyler, Tyler, Texas 75799, United States

Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas 66506, United States

Institute of Computational Comparative Medicine, Kansas State University, Manhattan, Kansas 66506, United States

Department of Chemistry, College of Sciences, University of Central Florida, Orlando, Florida 32816, United States

NanoScience Technology Center, University of Central Florida, Orlando, Florida 32826, United States

Department of Materials Science and Engineering, College of Engineering,, University of Central Florida, Orlando, Florida 32816, United States

Funding

National Institute of Biomedical Imaging and Bioengineering · University of Texas at Tyler · University of Florida

References (100+)

Show source-provided references
1. 10.1002/btm2.1014310.1002/btm2.10143 ↗
2. 10.1016/j.tifs.2017.11.01510.1016/j.tifs.2017.11.015 ↗
3. 10.1016/j.apmt.2019.10047310.1016/j.apmt.2019.100473 ↗
4. 10.1002/wnan.180810.1002/wnan.1808 ↗
5. 10.1007/s00204-017-2144-110.1007/s00204-017-2144-1 ↗
6. 10.1039/C1CS15188F10.1039/C1CS15188F ↗
7. 10.1289/ehp.828410.1289/ehp.8284 ↗
8. 10.1146/annurev-pharmtox-032320-11033810.1146/annurev-pharmtox-032320-110338 ↗
9. 10.3109/17435390.2012.69199810.3109/17435390.2012.691998 ↗
10. 10.3390/toxics909020410.3390/toxics9090204 ↗
11. 10.2147/IJN.S4662410.2147/IJN.S46624 ↗
12. 10.3109/17435390.2014.94040410.3109/17435390.2014.940404 ↗
13. 10.1080/17435390.2018.145992210.1080/17435390.2018.1459922 ↗
14. 10.1016/j.jconrel.2013.05.02510.1016/j.jconrel.2013.05.025 ↗
15. 10.1016/j.envint.2020.10550510.1016/j.envint.2020.105505 ↗
16. 10.1016/j.impact.2021.10037610.1016/j.impact.2021.100376 ↗
17. 10.3389/fdgth.2022.83859010.3389/fdgth.2022.838590 ↗
18. 10.1126/sciadv.aax264210.1126/sciadv.aax2642 ↗
19. 10.3390/nano1203051110.3390/nano12030511 ↗
20. 10.3390/pharmaceutics902001210.3390/pharmaceutics9020012 ↗
21. 10.1016/j.canlet.2008.04.02610.1016/j.canlet.2008.04.026 ↗
22. NCI. Spherical Nucleic Acid Nanoparticle Nu-0129 in Treating Patients with Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2016-02007 (accessed 2022-06-27).
23. 10.1016/j.jconrel.2019.05.00310.1016/j.jconrel.2019.05.003 ↗
24. 10.1016/j.jconrel.2005.08.02310.1016/j.jconrel.2005.08.023 ↗
25. 10.1039/C0CS00018C10.1039/C0CS00018C ↗
26. 10.1002/wnan.130410.1002/wnan.1304 ↗
27. 10.1073/pnas.223247910010.1073/pnas.2232479100 ↗
28. 10.1080/1071754049043389510.1080/10717540490433895 ↗
29. 10.1039/C1CS15237H10.1039/C1CS15237H ↗
30. 10.1016/j.taap.2008.12.02310.1016/j.taap.2008.12.023 ↗
31. 10.1038/s41598-019-48748-310.1038/s41598-019-48748-3 ↗
32. 10.1016/j.biomaterials.2007.12.03710.1016/j.biomaterials.2007.12.037 ↗
33. 10.1016/j.colsurfb.2008.07.00410.1016/j.colsurfb.2008.07.004 ↗
34. 10.2217/nnm.14.6010.2217/nnm.14.60 ↗
35. 10.2217/nnm.15.17710.2217/nnm.15.177 ↗
36. FDA. FDA’s Regulatory Science Program for Generic PLA/ PLGA-Based Drug Products. https://www.americanpharmaceuticalreview.com/Featured-Articles/188841-FDA-s-Regulatory-Science-Program-for-Generic-PLA-PLGA-Based-Drug-Products/. (accessed 2022-06-27).
37. FDA. Approvals of FDA-Regulated Products. https://www.fda.gov/news-events/approvals-fda-regulated-products (accessed 2022-06-27).
38. 10.1016/0142-9612(96)85754-110.1016/0142-9612(96)85754-1 ↗
39. 10.1080/21691401.2016.120226010.1080/21691401.2016.1202260 ↗
40. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
41. 10.1039/D0NR00039F10.1039/D0NR00039F ↗
42. 10.1208/s12249-017-0888-910.1208/s12249-017-0888-9 ↗
43. 10.1002/bdd.225510.1002/bdd.2255 ↗
44. 10.1016/j.ijpharm.2017.01.02110.1016/j.ijpharm.2017.01.021 ↗
45. 10.1002/adfm.20180681710.1002/adfm.201806817 ↗
46. 10.2147/IJN.S12188110.2147/IJN.S121881 ↗
47. 10.1016/j.addr.2012.09.03710.1016/j.addr.2012.09.037 ↗
48. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
49. 10.1002/adma.20170430710.1002/adma.201704307 ↗
50. 10.1002/jcp.2636110.1002/jcp.26361 ↗
51. 10.3109/10717544.2015.108859610.3109/10717544.2015.1088596 ↗
52. FDA. Drugs@FDA: FDA-Approved Drugs. Doxil (Liposomal). https://www.accessdata.fda.gov/Scripts/Cder/Daf/index.cfm?event=overview.process&ApplNo=050718 (accessed 2022-06-27).
53. Working P. K. · Hum. Exp. Toxicol. · 1996 · 15 · 751
54. 10.1023/A:101890771590510.1023/A:1018907715905 ↗
55. 10.3171/jns.1995.83.6.102910.3171/jns.1995.83.6.1029 ↗
56. 10.1177/09603271990180010310.1177/096032719901800103 ↗
57. 10.2147/IJN.S22871510.2147/IJN.S228715 ↗
58. 10.1016/0304-3835(96)04380-710.1016/0304-3835(96)04380-7 ↗
59. 10.1208/ps05043210.1208/ps050432 ↗
60. 10.1016/j.ab.2004.09.04610.1016/j.ab.2004.09.046 ↗
61. 10.1016/j.ejpb.2004.06.00910.1016/j.ejpb.2004.06.009 ↗
62. 10.1111/j.1749-6632.2000.tb07063.x10.1111/j.1749-6632.2000.tb07063.x ↗
63. 10.1080/08958370175340398010.1080/089583701753403980 ↗
64. 10.1158/1078-0432.CCR-0929-310.1158/1078-0432.CCR-0929-3 ↗
65. 10.1016/j.pupt.2007.04.00210.1016/j.pupt.2007.04.002 ↗
66. Pal A. · Anticancer Res. · 2005 · 25 · 331
67. 10.1016/S0168-3659(03)00271-210.1016/S0168-3659(03)00271-2 ↗
68. 10.1007/s00280005040910.1007/s002800050409 ↗
69. Perez-Soler R. · Clin. Cancer Res. · 1997 · 3 · 373
70. 10.1007/s00280-006-0235-410.1007/s00280-006-0235-4 ↗
71. 10.1016/S0168-3659(01)00343-110.1016/S0168-3659(01)00343-1 ↗
72. 10.1016/0009-3084(93)90070-J10.1016/0009-3084(93)90070-J ↗
73. 10.1080/106118602100007244710.1080/1061186021000072447 ↗
74. 10.1021/nl052396o10.1021/nl052396o ↗
75. 10.1021/nl070363y10.1021/nl070363y ↗
76. 10.1063/1.350248910.1063/1.3502489 ↗
77. 10.1021/nn901392m10.1021/nn901392m ↗
78. 10.1039/c2nr31064c10.1039/c2nr31064c ↗
79. 10.3390/pharmaceutics1403066710.3390/pharmaceutics14030667 ↗
80. 10.1002/bit.2325310.1002/bit.23253 ↗
81. 10.1021/la025733710.1021/la0257337 ↗
82. 10.1016/j.taap.2009.09.01510.1016/j.taap.2009.09.015 ↗
83. 10.1016/j.jconrel.2012.07.01910.1016/j.jconrel.2012.07.019 ↗
84. 10.1016/0142-9612(88)90033-610.1016/0142-9612(88)90033-6 ↗
85. 10.1016/j.nantod.2011.02.00310.1016/j.nantod.2011.02.003 ↗
86. 10.1002/mabi.20110015610.1002/mabi.201100156 ↗
87. 10.1021/acs.jafc.7b0362710.1021/acs.jafc.7b03627 ↗
88. 10.1016/j.jconrel.2016.11.03310.1016/j.jconrel.2016.11.033 ↗
89. 10.3390/pharmaceutics1302020810.3390/pharmaceutics13020208 ↗
90. 10.1021/bm100710310.1021/bm1007103 ↗
91. 10.1088/0957-4484/21/35/35510210.1088/0957-4484/21/35/355102 ↗
92. 10.1186/s12951-015-0156-710.1186/s12951-015-0156-7 ↗
93. 10.3390/ma1420597710.3390/ma14205977 ↗
94. 10.1016/j.msec.2020.11179310.1016/j.msec.2020.111793 ↗
95. 10.1023/A:102221900355110.1023/A:1022219003551 ↗
96. Derakhshandeh K. · Iran. J. Pharm. Res. · 2011 · 10 · 425
97. 10.1016/j.biomaterials.2009.01.05710.1016/j.biomaterials.2009.01.057 ↗
98. 10.1016/j.ijbiomac.2019.07.16810.1016/j.ijbiomac.2019.07.168 ↗
99. 10.1016/j.biomaterials.2007.05.02510.1016/j.biomaterials.2007.05.025 ↗
100. 10.1038/nnano.2011.5810.1038/nnano.2011.58 ↗